Vertex Pharmaceuticals's quarterly market cap
increased
from Sep. 2025 ($99,457 Mil) to Dec. 2025 ($115,149 Mil) but then
declined
from Dec. 2025 ($115,149 Mil) to Mar. 2026 ($113,494 Mil).
Vertex Pharmaceuticals's annual market cap
declined
from Dec. 2023 ($104,854 Mil) to Dec. 2024 ($103,470 Mil) but then
increased
from Dec. 2024 ($103,470 Mil) to Dec. 2025 ($115,149 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Vertex Pharmaceuticals's Enterprise Value for Today is $121,554 Mil.
Vertex Pharmaceuticals (NAS:VRTX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vertex Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Vertex Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals (VRTX) has a Market Cap of $126,814 Mil as of Jun. 30, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Vertex Pharmaceuticals and its competitors. According to the industry distribution chart, Vertex Pharmaceuticals ranks #1 out of 1428 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is Vertex Pharmaceuticals' Market Cap too high?
Vertex Pharmaceuticals' current Market Cap is $126,814 Mil. The Biotechnology industry median Market Cap is 114.03. Vertex Pharmaceuticals' value of $126,814 Mil is 111109.1% above this industry median. Based on the distribution chart, Vertex Pharmaceuticals ranks #1 out of 1428 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vertex Pharmaceuticals has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Market Cap compare to REGN and ALNY?
According to the Biotechnology industry distribution chart, Vertex Pharmaceuticals ranks #1 out of 1428 companies for Market Cap. This places Vertex Pharmaceuticals in the top 0% of its industry — outperforming the majority of peers. The industry median Market Cap is 114.03. Vertex Pharmaceuticals' value of $126,814 Mil is 111109.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.03, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vertex Pharmaceuticals's current Market Cap of $126,814 Mil is 111109.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Vertex Pharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 114.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vertex Pharmaceuticals's current Market Cap is $126,814 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (VRTX) is currently considered Fairly Valued. The stock's GF Value™ is $502.32, compared to a current price of $499.65 — trading 0.5% below its estimated fair value. The current Market Cap is $126,814 Mil and 111109.1% above the Biotechnology industry median of 114.03. Vertex Pharmaceuticals' overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Vertex Pharmaceuticals (VRTX), the current Market Cap is $126,814 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vertex Pharmaceuticals (VRTX) Overvalued in 2026?
Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued.
The current stock price of $499.65 is trading 0.5% below its estimated GF Value™ of $502.32.
GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.
Key valuation signals for VRTX:
Market Cap: $126,814 Mil
GF Value™: $502.32 vs. price of $499.65 (0.5% below fair value)
Industry Position: 111109.1% above the Biotechnology median (#1 of 1428)
No single metric tells the full story. See the VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
86GF Score
Get the complete analysis for VRTX
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRTX has been successfully added to your 
